Beyond ADHD, Other Areas Of CNS Commercial Focus
Beyond our initial focus on ADHD, the strategy of Neos Therapeutics, Inc. (Neos Therapeutics) is to apply our proprietary drug delivery technology platform to the development of additional drug candidates where either XR-ODT or XR oral suspension dosage forms of existing extended-release medications might address unmet medical needs.
Our technology is targeted to address some of the common issues in oral drug delivery, such as high peak to trough ratios, blood level spikes that induce unwanted side effects, wide variations in fed-fasted effect, suboptimal onset of action, suboptimal duration of effect, dose-dumping and single point failures of the delivery system.
Hydrocodone polistirex and chlorpheniramine polistirex extended-release (XR) liquid suspension
We manufacture and market a generic hydrocodone polistirex and chlorpheniramine polistirex extended-release (XR) oral suspension product which is equivalent to the branded product Tussionex®. Our hydrocodone polistirex and chlorpheniramine polistirex XR oral suspension is a Schedule II combination oral suspension. Please see Full Prescribing Information. In 2014, approximately 2.1 million prescriptions of Tussionex® and related generic products were sold.
Since its launch in September 2013, we have manufactured and utilized our DTRS® technology in the production of our generic hydrocodone polistirex and chlorpheniramine polistirex extended-release (XR) oral suspension product at our facilities in Grand Prairie, Texas. We sell our product to drug wholesalers in the United States.
Tussionex® is a Registered Trademark of UCB Group of Companies.